Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Скринер
Новости
О нас

ICCC - ImmuCell Corporation Последние новости | Finranks

Home

/

ICCC

I

ImmuCell Corporation (ICCC)

NCM – Цена в реальном времени. Валюта: USD

8.38

-0.07 (-0.83%)

При закрытии: May 12, 2026, 4:00 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2026

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2026

PORTLAND, Maine, May 07, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops and markets products to improve calf health and productivity, expects to report unaudited financial results for the quarter ended March 31, 2026 after the market closes on Thursday, May 14, 2026. The Company is planning to host a conference call on Friday, May 15, 2026, at 9:00 AM ET to review the unaudited financial results.

The Zacks Analyst Blog The Goldman Sachs, NextEra, Shopify, Landmark and ImmuCell

The Zacks Analyst Blog The Goldman Sachs, NextEra, Shopify, Landmark and ImmuCell

Goldman Sachs, NextEra Energy and Shopify lead top stock reports, highlighting strong gains, expanding operations and strategic shifts driving growth.

ImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board of Independent Directors

ImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board of Independent Directors

PORTLAND, Maine, April 13, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops and markets products to improve calf health and productivity, announced that Dr. Gilles Guillemette and Dr. Anthony DiMarco have been appointed to its Board of Directors, effective April 15, 2026. The Company also announced it is moving to a 7-person Board of Directors with six Independent Directors and the CEO, and that it will create a Strategy and Technology Committee of the Board of Directors.

ImmuCell Announces a 28.4% Increase in Product Sales in Q1 of 2026, based on Preliminary, Unaudited Sales Results

ImmuCell Announces a 28.4% Increase in Product Sales in Q1 of 2026, based on Preliminary, Unaudited Sales Results

PORTLAND, Maine, April 08, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced preliminary, unaudited sales results for the first quarter of 2026.

ImmuCell Appoints Former Elanco Animal Health Board Member Kathy Turner to Board

ImmuCell Appoints Former Elanco Animal Health Board Member Kathy Turner to Board

PORTLAND, Maine, March 18, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced that Kathy Turner has been appointed to its Board of Directors, effective April 1, 2026. Ms. Turner replaces Steven Rosgen, who is retiring from the Board after serving since January 2018.

ImmuCell 2025 Net Loss Narrows Y/Y as Sales & Margins Improve

ImmuCell 2025 Net Loss Narrows Y/Y as Sales & Margins Improve

ICCC's 2025 sales rise 4.3% y/y, with the gross margin expanding sharply, helping narrow its annual net loss despite asset write-downs and strategic shifts.

ImmuCell Corporation (ICCC) Q4 2025 Earnings Call Transcript

ImmuCell Corporation (ICCC) Q4 2025 Earnings Call Transcript

ImmuCell Corporation (ICCC) Q4 2025 Earnings Call Transcript

Видео

No Data

There is no data to display

Пресс-релизы

ImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board of Independent Directors

ImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board of Independent Directors

PORTLAND, Maine, April 13, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops and markets products to improve calf health and productivity, announced that Dr. Gilles Guillemette and Dr. Anthony DiMarco have been appointed to its Board of Directors, effective April 15, 2026. The Company also announced it is moving to a 7-person Board of Directors with six Independent Directors and the CEO, and that it will create a Strategy and Technology Committee of the Board of Directors.

ImmuCell Announces a 28.4% Increase in Product Sales in Q1 of 2026, based on Preliminary, Unaudited Sales Results

ImmuCell Announces a 28.4% Increase in Product Sales in Q1 of 2026, based on Preliminary, Unaudited Sales Results

PORTLAND, Maine, April 08, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced preliminary, unaudited sales results for the first quarter of 2026.

ImmuCell Appoints Former Elanco Animal Health Board Member Kathy Turner to Board

ImmuCell Appoints Former Elanco Animal Health Board Member Kathy Turner to Board

PORTLAND, Maine, March 18, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced that Kathy Turner has been appointed to its Board of Directors, effective April 1, 2026. Ms. Turner replaces Steven Rosgen, who is retiring from the Board after serving since January 2018.

ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2025

ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2025

PORTLAND, Maine, March 04, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health company that develops, manufactures and markets products that improve cattle health and productivity, today announced its unaudited financial results for the year ended December 31, 2025.